GlassScriptPhysician profile
Mahmood S Eisa
NPI 1184606824
$25,785.85
in general payments reported to CMS, 2019-2025
68 companies · $6,918 in 2025
The $6,918 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,721 · 2020: $2,034 · 2021: $3,069 · 2022: $2,613 · 2023: $3,763 · 2024: $4,669 · 2025: $6,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Travel and Lodging: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,194.18 |
| Travel and Lodging | $1,155.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,891.11 | 2019-2025 | Briviact, Fintepla, Rystiggo |
| Abbvie INC. | $1,752.45 | 2019-2025 | |
| Boston Scientific Corporation | $1,544.73 | 2021-2025 | Vercise, General - Dbs |
| Lundbeck LLC | $1,276.89 | 2020-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $1,233.22 | 2020-2025 | Xcopri |
| Teva Pharmaceuticals USA, INC. | $981.41 | 2019-2025 | Austedo Xr, Austedo Xr |
| Jazz Pharmaceuticals INC. | $936.29 | 2019-2025 | |
| Lilly USA, LLC | $920.93 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $814.63 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $772.31 | 2019-2025 | Ultomiris |
| Neurelis, INC. | $731.73 | 2020-2025 | Valtoco |
| Pfizer INC. | $695.47 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $624.48 | 2021-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $616.96 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $583.24 | 2019-2025 | Dysport |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Eisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.